Close

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US Sep 9, 2020 06:45PM
FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US Sep 9, 2020 06:24PM
Innoviva (INVA), GlaxoSmithKline (GSK) Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint May 2, 2019 12:22PM
Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint May 2, 2019 12:18PM
GSK (GSK), Innoviva (INVA) announce once-daily Trelegy Ellipta gains expanded COPD indication in Europe Nov 9, 2018 07:09AM


Nov 9, 2018 07:01AM Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
Sep 21, 2018 07:31AM Innoviva (INVA) and GSK (GSK) Announce Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication
Sep 21, 2018 07:30AM Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe
Apr 24, 2018 12:55PM Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD